Prognostic value of consolidation-to-tumor ratio on computed tomography in NSCLC: a meta-analysis

Table 3 Subgroup analysis for DFS/RFS/PFS

	Number of studies	HR	95% CI	P value	Heterogeneity (P, I² (%))
Progress-free survival	22	1.42	1.27–1.59	< 0.01	< 0.01, 81.9
Country
China	10	1.83	1.39–2.42	< 0.01	< 0.01, 87.7
Japan	9	2.92	1.47–5.81	0.002	< 0.01, 72.6
Korea	2	2.35	1.37–4.05	0.278	0.692, 0.0
Turkey	1	0.63	0.23–1.72	0.043	–, –
Cut-off value
0.25	1	2.04	0.84–4.96	0.116	–, –
0.50	13	2.73	1.63–4.58	< 0.01	< 0.01, 78.7
0.75	2	2.03	1.13–3.66	0.018	0.117,59.3
0.85	1	2.60	0.16–42.12	0.501	–, –
Continuous variable	5	1.46	1.08–1.99	0.015	< 0.01,90.7
Source of HR
Reported	16	1.36	1.22–1.52	< 0.01	< 0.01, 84.8
Estimated	6	1.85	1.21–2.83	0.004	0.264, 22.6
Histology type
Adenocarcinoma	15	2.06	1.48–2.87	< 0.01	< 0.01,83.6
NSCLC	7	1.44	1.02–2.02	0.037	< 0.01,78.9

ISSN: 1477-7819